The group's findings are published in Nature Nanotechnology. Getting enough anticancer drugs into a tumour is often difficult, and a potential strategy to overcome this challenge involves binding the medications to albumin, the most abundant protein in blood.
The strategy relies on tumours' large appetite for protein nutrients that fuel malignant growth. When consuming available albumin, the tumours will inadvertently take in the attached drugs.
A popular albumin-bound drug approved by the U.S. Food and Drug Administration is nanoparticle albumin-bound paclitaxel (nab-PTX), and it has been successfully used to treat late-stage lung and pancreatic cancers.
"Not all patients respond to nab-PTX, though, and the effectiveness of its delivery to tumours has been mixed, owing to an incomplete understanding of how albumin impacts drug delivery and actions," says senior author Miles Miller, PhD, a principal investigator in the MGH Center for Systems Biology and assistant professor of Radiology at Harvard Medical School.
To provide insights, Miller and his colleagues assessed the delivery of nab-PTX to tumours at a single-cell resolution in mouse models of cancer.
Using 3D microscopy and what's called tissue clearing technology, the team found that cancer cells can take up a significant amount of nab-PTX, and that the consumption of these drugs is controlled by signalling pathways that are involved in the cells' uptake of nutrients such as albumin.
"This discovery suggested that if we could manipulate these pathways, we might be able to trick cancer cells into a nutrient-starved state, thereby enhancing their consumption of nab-PTX," explains Ran Li, PhD, first author on the study and an instructor in the MGH Department of Radiology and the Center for Systems Biology.
Indeed, treating tumours with an inhibitor of insulin-like growth factor 1 receptor, an important component of one of the signalling pathways, improved the accumulation of nab-PTX in tumours and boosted its effectiveness.
"These results offer new possibilities to improve delivery of albumin-bound drugs in patients with diverse types of cancer," says Miller.
Read the original article on ANI News.